Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.

Americans are getting slimmer. The rise of GLP-1 medications has transformed the way Americans lose weight, and the data supports that: ...

O n any given day, millions of people in the U.S. are trying to lose weight. Recent data from the Centers for Disease Control and Prevention reports that a little over 40% of adul ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands Mounjaro and Zepbound, in India by 2025. The proposed dosages ranged from 2.5 ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep ... physical activity and a reduced-calorie diet. Obstructive sleep apnea occurs when ...

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

It has helped her lose around 55 pounds, experience fewer symptoms from her chronic inflammatory conditions and pursue a healthier diet and ... insurance plan covers Zepbound can pay as low ...